| Medical and Health Sciences | 2021-2025 | 59 | CN 4 | 99.99 |
| Biological Sciences | 2021-2025 | 92 | CN 36 | 99.92 |
| Oncology | Lifetime | 190 | CN 4 | 99.69 |
| Pulmonary and Respiratory Medicine | Lifetime | 372 | CN 6 | 99.53 |
| Cancer Research | Lifetime | 158 | CN 8 | 99.14 |
| Pathology and Forensic Medicine | Lifetime | 728 | CN 17 | 96.63 |
| Complementary and Alternative Medicine | Lifetime | 895 | CN 90 | 87.48 |
| Hepatology | Lifetime | 882 | CN 55 | 79.35 |
| Biotechnology | Lifetime | 955 | CN 65 | 64.81 |
| Oncology | 2021-2025 | 12 | CN 1 | 99.92 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 38 | CN 6 | 99.84 |
| Molecular Biology | 2021-2025 | 95 | CN 43 | 99.62 |
| Surgery | 2021-2025 | 94 | CN 5 | 99.45 |
| Cancer Research | 2021-2025 | 49 | CN 23 | 98.16 |
| Immunology | 2021-2025 | 159 | CN 37 | 96.63 |
| Neuroscience of Neurology | 2021-2025 | 96 | CN 12 | 95.16 |
| Pathology and Forensic Medicine | 2021-2025 | 160 | CN 12 | 95.93 |
| Radiology, Nuclear Medicine and Imaging | 2021-2025 | 448 | CN 46 | 90.79 |
| Gastric Cancer Management and Outcomes | Lifetime | 37 | CN 1 | 99.82 |
| Colorectal Cancer Treatments and Studies | Lifetime | 73 | CN 3 | 99.68 |
| Cancer-related molecular mechanisms research | Lifetime | 227 | CN 101 | 99.07 |
| Cancer, Hypoxia, and Metabolism | Lifetime | 252 | CN 11 | 99.23 |
| Gastrointestinal Tumor Research and Treatment | Lifetime | 97 | CN 1 | 99.27 |
| Ferroptosis and cancer prognosis | Lifetime | 95 | CN 39 | 98.49 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 307 | CN 12 | 99.26 |
| Inflammatory Biomarkers in Disease Prognosis | Lifetime | 85 | CN 10 | 97.38 |
| Metastasis and carcinoma case studies | Lifetime | 172 | CN 11 | 98.31 |
| RNA modifications and cancer | Lifetime | 758 | CN 93 | 98.56 |
| Cancer Genomics and Diagnostics | Lifetime | 595 | CN 10 | 98.90 |
| Pancreatic and Hepatic Oncology Research | Lifetime | 579 | CN 11 | 98.65 |
| Esophageal Cancer Research and Treatment | Lifetime | 259 | CN 6 | 98.46 |
| MicroRNA in disease regulation | Lifetime | 698 | CN 259 | 97.89 |
| Cancer Treatment and Pharmacology | Lifetime | 504 | CN 4 | 98.59 |
| HER2/EGFR in Cancer Research | Lifetime | 364 | CN 3 | 98.41 |
| Genetic factors in colorectal cancer | Lifetime | 523 | CN 10 | 98.19 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | Lifetime | 535 | CN 43 | 97.96 |
| Circular RNAs in diseases | Lifetime | 498 | CN 265 | 97.06 |
| Cancer Mechanisms and Therapy | Lifetime | 384 | CN 56 | 96.10 |
| Colorectal Cancer Screening and Detection | Lifetime | 752 | CN 18 | 97.40 |
| Colorectal and Anal Carcinomas | Lifetime | 646 | CN 13 | 96.40 |
| Gene expression and cancer classification | Lifetime | 652 | CN 67 | 95.06 |
| Barrier Structure and Function Studies | Lifetime | 906 | CN 40 | 85.86 |
| Gastric Cancer Management and Outcomes | 2021-2025 | 7 | CN 1 | 99.91 |
| Esophageal Cancer Research and Treatment | 2021-2025 | 10 | CN 1 | 99.60 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 17 | CN 1 | 99.76 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 59 | CN 9 | 99.75 |
| Genetic factors in colorectal cancer | 2021-2025 | 27 | CN 2 | 98.96 |
| Pancreatic and Hepatic Oncology Research | 2021-2025 | 79 | CN 6 | 98.97 |
| RNA modifications and cancer | 2021-2025 | 121 | CN 80 | 98.70 |
| Cancer Genomics and Diagnostics | 2021-2025 | 180 | CN 8 | 98.64 |
| HER2/EGFR in Cancer Research | 2021-2025 | 65 | CN 3 | 98.91 |
| Gastrointestinal Tumor Research and Treatment | 2021-2025 | 58 | CN 13 | 97.80 |
| Barrier Structure and Function Studies | 2021-2025 | 11 | CN 1 | 95.77 |
| Epigenetics and DNA Methylation | 2021-2025 | 252 | CN 95 | 95.59 |
| Lung Cancer Treatments and Mutations | 2021-2025 | 274 | CN 48 | 98.21 |
| Colorectal Cancer Screening and Detection | 2021-2025 | 217 | CN 20 | 96.15 |
| Immune cells in cancer | 2021-2025 | 326 | CN 179 | 93.91 |
| Colorectal and Anal Carcinomas | 2021-2025 | 187 | CN 13 | 94.41 |
| Immunotherapy and Immune Responses | 2021-2025 | 593 | CN 167 | 93.52 |
| Cancer-related molecular mechanisms research | 2021-2025 | 860 | CN 660 | 93.97 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 469 | CN 69 | 93.21 |
| Cancer-related gene regulation | 2021-2025 | 265 | CN 174 | 89.63 |
| Colorectal Cancer Surgical Treatments | 2021-2025 | 535 | CN 79 | 92.47 |
| Ferroptosis and cancer prognosis | 2021-2025 | 806 | CN 684 | 90.93 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | 2021-2025 | 802 | CN 193 | 89.43 |
| Head and Neck Cancer Studies | 2021-2025 | 983 | CN 176 | 88.70 |
| Angiogenesis and VEGF in Cancer | 2021-2025 | 181 | CN 28 | 81.20 |
| interferon and immune responses | 2021-2025 | 805 | CN 441 | 82.09 |
| Inflammatory Biomarkers in Disease Prognosis | 2021-2025 | 526 | CN 220 | 80.00 |
| Metastasis and carcinoma case studies | 2021-2025 | 643 | CN 159 | 81.66 |
| NF-κB Signaling Pathways | 2021-2025 | 494 | CN 201 | 49.30 |
